| A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C (NCT01087944) | Hoffmann-La Roche | 2010-03-01 |
| A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 (NCT01057667) | Hoffmann-La Roche | 2010-02-01 |
| Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients (NCT01062659) | University of Ulm | 2010-02-01 |
| An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) (NCT01200225) | Hoffmann-La Roche | 2010-02-01 |
| Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2) (NCT01023035) | Merck Sharp & Dohme LLC | 2009-12-07 |
| A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response (NCT01033448) | Hoffmann-La Roche | 2009-12-01 |
| A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028) (NCT00943761) | Merck Sharp & Dohme LLC | 2009-10-23 |
| ADHEPTA Study: Adherence Questionnaire in Hepatitis C (NCT00998621) | Fundacion IMIM | 2009-10-01 |
| A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection (NCT00963885) | Hoffmann-La Roche | 2009-08-01 |
| A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 (NCT01185860) | Hoffmann-La Roche | 2009-08-01 |
| A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients (NCT00996476) | Janssen Pharmaceutical K.K. | 2009-07-01 |
| 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV) (NCT00953589) | Biolex Therapeutics, Inc. | 2009-07-01 |
| Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) (NCT00910624) | Merck Sharp & Dohme LLC | 2009-06-22 |
| Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) (NCT01098097) | Merck Sharp & Dohme LLC | 2009-06-01 |
| An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C (NCT02557646) | Hoffmann-La Roche | 2009-05-01 |
| 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients (NCT00905632) | Boehringer Ingelheim | 2009-05-01 |
| Interferon α 2b Pharmacovigilance Study (NCT01841775) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2009-05-01 |
| A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols (NCT00800735) | Hoffmann-La Roche | 2009-04-01 |
| Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336) (NCT00863109) | Merck Sharp & Dohme LLC | 2009-04-01 |
| Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients (NCT00782301) | ViiV Healthcare | 2009-03-01 |
| Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV (NCT00863239) | Biolex Therapeutics, Inc. | 2009-03-01 |
| A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients (NCT02556307) | Hoffmann-La Roche | 2009-03-01 |
| Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV (NCT02027493) | National Liver Institute, Egypt | 2009-02-01 |
| Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED) (NCT00845065) | Merck Sharp & Dohme LLC | 2009-02-01 |
| An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN) (NCT00704756) | Merck Sharp & Dohme LLC | 2009-01-01 |
| Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) (NCT00725842) | Merck Sharp & Dohme LLC | 2009-01-01 |
| A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients (NCT00801255) | Hoffmann-La Roche | 2008-11-01 |
| Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients (NCT00803309) | HepNet Study House, German Liverfoundation | 2008-11-01 |
| A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) (NCT00797745) | Merck Sharp & Dohme LLC | 2008-11-01 |
| POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin). (NCT00700401) | Hoffmann-La Roche | 2008-11-01 |
| Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2) (NCT00774397) | Boehringer Ingelheim | 2008-10-01 |
| A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) (NCT01429792) | Hoffmann-La Roche | 2008-09-25 |
| Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED) (NCT00708500) | Merck Sharp & Dohme LLC | 2008-08-01 |
| Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (NCT00705432) | Merck Sharp & Dohme LLC | 2008-08-01 |
| Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C (NCT00718172) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2008-07-11 |
| ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632) (NCT00856024) | Merck Sharp & Dohme LLC | 2008-07-01 |
| Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) (NCT00724451) | Merck Sharp & Dohme LLC | 2008-07-01 |
| A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response (NCT00623428) | Hoffmann-La Roche | 2008-06-01 |
| Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) (NCT00705224) | Merck Sharp & Dohme LLC | 2008-05-01 |
| Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181) (NCT00723645) | Merck Sharp & Dohme LLC | 2008-04-01 |
| PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b (NCT01066819) | Hoffmann-La Roche | 2008-01-01 |
| Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED) (NCT00686777) | Merck Sharp & Dohme LLC | 2008-01-01 |
| A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection (NCT00561353) | Tibotec Pharmaceuticals, Ireland | 2008-01-01 |
| A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection (NCT00561015) | Tibotec BVBA | 2007-12-01 |
| A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection. (NCT00517439) | Hoffmann-La Roche | 2007-12-01 |
| Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209) (NCT00724464) | Merck Sharp & Dohme LLC | 2007-12-01 |
| Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients (NCT02176525) | Boehringer Ingelheim | 2007-12-01 |
| Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection (NCT00565539) | ZymoGenetics | 2007-12-01 |
| Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED) (NCT00724373) | Merck Sharp & Dohme LLC | 2007-11-01 |
| Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients (NCT00553930) | Sociedad Andaluza de Enfermedades Infecciosas | 2007-11-01 |
| Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease (NCT00516321) | GlaxoSmithKline | 2007-10-01 |
| PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b (NCT01066793) | Hoffmann-La Roche | 2007-10-01 |
| Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease (NCT00529568) | GlaxoSmithKline | 2007-10-01 |
| Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced (NCT00793793) | Boehringer Ingelheim | 2007-09-01 |
| 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2) (NCT00761735) | Merck Sharp & Dohme LLC | 2007-07-01 |
| A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure. (NCT00474955) | Hoffmann-La Roche | 2007-07-01 |
| Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695) (NCT01081158) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland (NCT00473993) | Seidenberg, Arztpraxis A., M.D. | 2007-07-01 |
| The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) (NCT00483938) | Hoffmann-La Roche | 2007-06-01 |
| Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) (NCT00687219) | Merck Sharp & Dohme LLC | 2007-06-01 |
| PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a) (NCT01070550) | Hoffmann-La Roche | 2007-06-01 |
| Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection (NCT02716779) | Hoffmann-La Roche | 2007-04-01 |
| Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303) (NCT00493805) | Merck Sharp & Dohme LLC | 2007-04-01 |
| Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) (NCT00689390) | Merck Sharp & Dohme LLC | 2007-02-20 |
| A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C (NCT00394277) | Hoffmann-La Roche | 2007-02-01 |
| A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels (NCT02726022) | Hoffmann-La Roche | 2007-02-01 |
| Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions (NCT01908660) | Valme University Hospital | 2007-01-01 |
| SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1. (NCT00412334) | Hoffmann-La Roche | 2007-01-01 |
| Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED) (NCT00423800) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773) (NCT00686881) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus (NCT00529321) | Transgene | 2006-12-01 |
| Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults (NCT00439959) | GlaxoSmithKline | 2006-10-01 |
| Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C (NCT00265642) | ANRS, Emerging Infectious Diseases | 2006-10-01 |
| A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection. (NCT00389298) | Vertex Pharmaceuticals Incorporated | 2006-10-01 |
| A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection. (NCT00377182) | Hoffmann-La Roche | 2006-09-01 |
| Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC (NCT00375661) | Kyoto University | 2006-09-01 |
| Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) (NCT00724854) | Merck Sharp & Dohme LLC | 2006-08-01 |
| Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection (NCT00351403) | FGK Clinical Research GmbH | 2006-07-01 |
| Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients (NCT00495131) | National Taiwan University Hospital | 2006-06-01 |
| Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED) (NCT00727077) | Merck Sharp & Dohme LLC | 2006-06-01 |
| Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis C (NCT00399815) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2006-06-01 |
| PegIntron Injection Surveillance Plan (Study P04123) (NCT00723931) | Merck Sharp & Dohme LLC | 2006-06-01 |
| A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection (NCT00353418) | Hoffmann-La Roche | 2006-06-01 |
| Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy. (NCT00323804) | ANRS, Emerging Infectious Diseases | 2006-05-01 |
| Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) (NCT00378599) | Merck Sharp & Dohme LLC | 2006-05-01 |
| APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin (NCT02850289) | Hoffmann-La Roche | 2006-04-01 |
| Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690) (NCT00725205) | Merck Sharp & Dohme LLC | 2006-03-01 |
| Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED) (NCT00724230) | Merck Sharp & Dohme LLC | 2006-02-01 |
| A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C (NCT00800748) | Hoffmann-La Roche | 2006-02-01 |
| Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED) (NCT00705666) | Merck Sharp & Dohme LLC | 2006-02-01 |
| An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection (NCT00292084) | BioWest Therapeutics Inc | 2006-02-01 |
| Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED) (NCT00687544) | Merck Sharp & Dohme LLC | 2005-12-01 |
| Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy (NCT00299923) | University of Hamburg-Eppendorf | 2005-11-01 |
| Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C (NCT00305383) | Bausch Health Americas, Inc. | 2005-11-01 |
| Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant (NCT00135694) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-10-01 |
| Prediction of Hepatitis C Recurrence in Liver Transplant Recipients (NCT00867243) | Northwestern University | 2005-10-01 |
| Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED) (NCT00705263) | Schering-Plough | 2005-10-01 |
| Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671) (NCT00728494) | Merck Sharp & Dohme LLC | 2005-10-01 |
| Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED) (NCT00723632) | Merck Sharp & Dohme LLC | 2005-09-01 |
| A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection (NCT00217139) | BioWest Therapeutics Inc | 2005-09-01 |